eLifeNeurosciencePeer-reviewed journal article
Rescue of behavioral and electrophysiological phenotypes in a Pitt-Hopkins syndrome mouse model by genetic restoration of Tcf4 expression
Hyojin KimiD, Eric B. Gao, Adam DraperiD, Noah BerensiD, Hanna VihmaiD, Xinyuan ZhangiD, Alexandra Higashi-Howard, Kimberly RitolaiD, Jeremy M. SimoniD, Andrew John KennedyiD, Benjamin D. PhilpotiD
Abstract
Pitt-Hopkins syndrome (PTHS) is a neurodevelopmental disorder caused by monoallelic mutation or deletion in the transcription factor 4 (TCF4) gene. Individuals with PTHS typically present in the first year of life with developmental delay and exhibit intellectual disability, lack of speech, and motor incoordination. There are no effective treatments available for PTHS, but the root cause of the disorder, TCF4 haploinsufficiency, suggests that it could be treated by normalizing TCF4 gene expression. Here we performed proof-of-concept viral gene therapy experiments using a conditional Tcf4 mouse model of PTHS and found that postnatally reinstating Tcf4 expression in neurons improved anxiety-like behavior, activity levels, innate behaviors, and memory. Postnatal reinstatement also partially corrected EEG abnormalities, which we characterized here for the first time, and the expression of key TCF4-regulated genes. Our results support a genetic normalization approach as a treatment strategy for PTHS, and possibly other TCF4-linked disorders.
- Citations
- 30
- FWCI
- 3.62
- Field percentile
- top 6%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Juvenile reinstatement of TCF4 in Pitt-Hopkins syndrome model mice reveals a critical window for genetic intervention
Lucas M. James, Carlee A. Friar, … Benjamin D. Philpot·bioRxiv·Dec 24, 2025
- Tcf4 Deficiency Causes Recurrent Seizures in Mice
Laura Craciun, Vivianna R. DeNittis, … Kaoru Saijo·bioRxiv·Nov 1, 2024
- Evaluation of Nav1.8 as a therapeutic target for Pitt Hopkins Syndrome
Keri Martinowich, Debamitra Das, … Brady J. Maher·Molecular PsychiatryPeer-reviewed·Oct 12, 2022
- Clemastine fumarate enhances myelination and promotes functional recovery in a syndromic ASD mouse model of Pitt-Hopkins Syndrome
Joseph F. Bohlen, Colin M. Cleary, … Brady J. Maher·bioRxiv·May 3, 2022
- TCF4 mutations disrupt synaptic function through dysregulation of RIMBP2 in patient-derived cortical neurons
Brittany A. Davis, Huei-Ying Chen, … Brady J. Maher·Biological PsychiatryPeer-reviewed·Apr 1, 2024
- Characterization of astrocyte density in the Pitt-Hopkins Syndrome mouse model of ASD
Sara M. Stump, Joseph F. Bohlen, … Brady J. Maher·bioRxiv·Jul 10, 2025